Al's Comment:

 Unfrotunately, this trial failed to show any improvement by adding a Parp inhibitor to the standard treatment for MGMT Unmethylated Glioblastoma. It highlights the need to develop new treatments, as survival was only 1 year in both the experimental group and the standard of care group.

Posted on: 05/20/2021

A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!